Pharmacoepidemiology and "in silico" drug evaluation: is there common ground?

Journal of Clinical Epidemiology

Volumn 61, Issue 3, 2008, Pages 205-206

  Stürmer, Til ^a   Rothman, Kenneth J ^a,b   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE;

ARTICLE; ARTIFACT; DRUG BIOAVAILABILITY; DRUG SCREENING; HIP FRACTURE; HUMAN; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SIMULATION;

EID: 38549112939     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2007.07.006     Document Type: Note

References (14)

1. Avorn J. Powerful medicines: the benefits, risks, and costs of prescription drugs (2004), Knopf, New York
2. Strom BL, ed. Pharmacoepidemiology. 4th ed. West Sussex: Wiley & Sons; 2005.
3. Boissel J.P., Cucherat M., Nony P., Chebaud S., Gueffier F., Wright J.M., et al. New insights on the relation between untreated and treated outcomes for a given therapy. J Clin Epidemiol 61 (2008) 301-307
4. Rothman K.J. Causes. Am J Epidemiol 104 (1976) 587-592
5. Rothman K.J., and Poole C. A strengthening programme for weak associations. Int J Epidemiol 17 (1988) 955-959
6. In: Rothman K.J., and Greenland S. (Eds). Modern Epidemiology. 2nd ed. (1998), Lippincott Williams & Wilkins, Philadelphia
7. Stürmer T., Rothman K.J., and Glynn R.J. Insights into different results from different causal contrasts in the presence of effect-measure modification. Pharmacoepidemiol Drug Saf 15 (2006) 698-709
8. Institute of Medicine Committee on the Assessment of the US Drug Safety System. The future of drug safety: promoting and protecting the health of the public (2007), National Academy Press, Washington DC
9. Maldonado G., and Greenland S. The importance of critically interpreting simulation studies. Epidemiology 8 (1997) 453-456
10. Stürmer T., Schneeweiss S., Rothman K.J., Avorn J., and Glynn R.J. Performance of propensity score calibration-a simulation study. Am J Epidemiol 165 (2007) 1110-1118
11. French D.D., Chirikos T.N., Spehar A., Campbell R., Means H., and Bulat T. Effect of concomitant use of benzodiazepines and other drugs on the risk of injury in a veterans population. Drug Safety 28 (2005) 1141-1150
12. Muzikant A.L., and Penland R.C. Models for profiling the potential QT prolongation risk of drugs. Curr Opin Drug Discov Devel 5 (2002) 127-135
13. Pappalardo F., Lollini P.L., Castiglione F., and Motta S. Modeling and simulation of cancer immunoprevention vaccine. Bioinformatics 21 (2005) 2891-2897
14. Avorn J. The marketplace can't give us the drug safety data we need. MedGenMed 9 (2007) 29